Lates News

The announcement of the Group of Chinese Drug Group: The Group has developed Aprepitant Injection (4.4ml:32mg), which has obtained the drug registration approval from the National Medical Products Administration of the People's Republic of China. This product is a new generation NK-1 receptor antagonist, a submicellar injection that can selectively bind to NK-1 receptors in the brain and antagonize substance P effectively to prevent acute and delayed vomiting. This product is suitable for preventing postoperative nausea and vomiting (PONV) in adults. Compared to traditional forms of Aprepitant, this product has a rapid onset of action, significantly improves patient compliance, and effectively reduces the occurrence of allergic reactions in clinical use. It provides a better medication choice for the prevention of postoperative nausea and vomiting in adults.